RecruitingPhase 3NCT05509933
Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation
Sponsor
Henry Ford Health System
Enrollment
110 participants
Start Date
Nov 9, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria2
- Patients 18-80 years of age with a diagnosis of a hematological malignancy
- Meet the BMT program criteria to undergo hematopoietic stem cell transplantation for hematologi malignancies
Exclusion Criteria2
- Patients enrolled in investigational clinical trials
- Sct for non hematologic malignancies
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGBudesonide
budesonide starting day 5 after transplant
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05509933